Normosang (Human Hemin)

Human Hemin, the active ingredient in Normosang, is a hemin (heme) preparation presented as an injectable solution (lyophilized powder for reconstitution) for intravenous use. It provides exogenous heme to patients with acute intermittent porphyria, helping to terminate acute attacks by reducing the accumulation of toxic porphyrin precursors. The product is authorized for use in the European Union and is administered under medical supervision.

GNH USA supplies Normosang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide.

Normosang is used in the management of acute porphyria attacks by supplying heme to down‑regulate the heme biosynthetic pathway.

Acute intermittent porphyria: reduces severity and duration of acute attacks. Acute hepatic porphyria (including variegate and hereditary types): helps control porphyrin precursor buildup. Prevention of recurrent attacks: used in patients with established porphyria to lower the frequency of future crises.

Common Side Effects: - Infusion site pain or phlebitis - Nausea or vomiting - Headache - Fever or chills - Mild hypotension - Transient elevation of liver enzymes

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Hemolysis, especially in patients with G6PD deficiency - Acute renal impairment - Severe hypotension requiring intervention - Thrombophlebitis extending beyond the infusion site - Coagulopathy or bleeding disorders

Normosang should be administered only under specialist supervision with appropriate monitoring.

Monitor liver function: assess hepatic enzymes before and during therapy. Assess hypersensitivity: screen for prior allergic reactions to hemin products. Use in acute attacks only: avoid routine prophylactic use without clinical indication. Reconstitute correctly: follow manufacturer instructions to ensure solution stability. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Human Hemin may interact with other medications that affect heme metabolism or coagulation.

Major Interactions (Avoid): - Concomitant use with other heme‑containing products: risk of iron overload. - Live vaccines: potential alteration of immune response.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor INR and adjust dose if needed. - Drugs metabolized by hepatic enzymes (e.g., cytochrome P450 substrates): observe for altered drug levels. - Iron supplements: monitor iron status to prevent excess accumulation.